Skip to main content

Perioperative Anti-platelet Therapy for Patients undergoing Carotid Endarterectomy

CBE ID
0465
Endorsed
Endorsement Status
1.1 New or Maintenance
E&M Cycle
Is Under Review
No
Next Planned Maintenance Review
Surgery Spring 2024
1.3 Measure Description

Percentage of patients undergoing carotid endarterectomy (CEA) who are taking an anti-platelet agent (aspirin or clopidogrel or equivilant such as aggrenox/tiglacor etc) within 48 hours prior to surgery and are prescribed this medication at hospital discharge following surgery

        • 1.14 Numerator

          Patients over age 18 undergoing carotid endarterectomy who received anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists within 48 hours prior to the initiation of surgery AND are prescribed this medication at hospital discharge following surgery.

        • 1.15 Denominator

          Patients over age 18 undergoing carotid endarterectomy.

        • Exclusions

          Patients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on heparin or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery. Patients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery.

        • Most Recent Endorsement Activity
          Endorsed Surgery Endorsement Maintenance Project 2014
          Initial Endorsement
          Last Updated